At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
In Brief
A Phase 2 clinical trial evaluating Sunitinib for Mucosal Lentiginous Melanoma and Acral Lentiginous Malignant Melanoma. Completed, enrolled 52 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. Suninitib is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certain cancer cells which allow the malignant cells to multiply and spread due to a change in the genetic make up of the cancer cell.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedDec 2007
Primary CompletionAug 2014
TodayJul 2026
First PostedDec 20, 2007
Enrollment StartAug 1, 2007
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 18.5 years ago
Interventions
Sunitinibdrug